We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App





BPM Presents Urine-Based Kidney Disease Risk Test at MEDICA 2026

By HospiMedica International staff writers
Posted on 17 Nov 2026

Bio Preventive Medicine Corp. More...

(BPM, Hsinchu County, Taiwan) showcases its DNlite urinary biomarker test at MEDICA 2026, taking place November 16–19 in Düsseldorf, Germany. The company specializes in post-translationally modified protein biomarkers and in vitro diagnostics (IVD), focusing on identifying patients at risk of kidney disease progression before substantial deterioration in renal function occurs.

The featured DNlite (uPTM-FetA ELISA) test is designed to assess kidney function prognosis by measuring urinary post-translationally modified Fetuin-A (uPTM-FetA). The biomarker is associated with cellular stress involving kidney podocytes and tubular cells. The assay aims to distinguish patients at increased risk of rapid kidney function decline from those with more stable renal function.

Conventional kidney assessments rely on markers such as the urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR). However, these measurements may not fully capture early kidney injury or distinguish patients likely to experience rapid progression. DNlite is designed to complement existing tests by providing additional prognostic information to support earlier risk assessment.

The assay requires a routine random urine sample, avoiding the need for fasting blood collection or invasive procedures. Its ELISA format is intended for use in qualified clinical laboratories. DNlite provides prognostic information that can be considered alongside conventional clinical assessments, potentially supporting more individualized monitoring and treatment planning.

DNlite has obtained European Union In Vitro Diagnostic Regulation (IVDR) Class C certification for prognostic assessment in patients with type 2 diabetes and kidney transplant recipients. BPM reports commercial authorizations across more than 42 countries in Europe, the Middle East, Asia, and Latin America, supporting the test's availability in multiple international markets.

Clinical evidence supporting DNlite includes research involving participants from the CREDENCE trial. An analysis of 2,429 patients with type 2 diabetes and chronic kidney disease found that urinary uPTM-FetA independently predicted adverse renal outcomes beyond conventional markers, including UACR and eGFR. The findings suggest that the biomarker may provide additional information for identifying patients at increased risk of progression.

The company is also exploring the adaptation of its uPTM-FetA biomarker technology to automated clinical chemistry and chemiluminescence immunoassay platforms. These development initiatives aim to extend the test beyond its existing ELISA format and support integration into routine laboratory workflows through partnerships with diagnostic instrument manufacturers.

Additional collaboration opportunities include regional distribution, reference laboratory testing, pharmaceutical clinical trials, and integrated kidney care programs. BPM is investigating the potential use of its biomarkers to identify patients at increased risk of disease progression for clinical studies and support research into treatment monitoring and precision kidney care.

BPM exhibits at Booth C26-1 in Hall 3 within the Taiwan Flagship Pavilion. The company uses its participation at MEDICA 2026 to engage with diagnostic manufacturers, laboratory operators, healthcare providers, and research partners interested in urinary biomarker testing and kidney disease risk assessment technologies.


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Gold Member
Blood Gas Analyzer
i-Check200
Resorbable Bovine Collagen Membrane
GenDerm
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image Credit: iStock

Updated Head Injury Guidelines Support Risk-Based CT and Observation Decisions

Head injuries are a common reason for emergency department visits, with most cases classified as mild. However, clinicians must identify patients at risk of intracranial bleeding or other serious injuries... Read more

Patient Care

view channel
Image: A view inside the custom virtual reality environment used in the study: a calm room with a teddy bear, soft colors and large windows looking out over the sea. (Image Credit: Walaa S. Abu Rukbah et al., Virginia Commonwealth University; CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Virtual Reality Program May Reduce Anxiety Before Pediatric Surgery

Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more

Medical Imaging

view channel
Image Credit: Adobe Stock

Lung Ultrasound Predicts Progression of Interstitial Lung Abnormalities in Rheumatoid Arthritis

Interstitial lung abnormalities are a pulmonary concern in patients with rheumatoid arthritis, requiring monitoring to detect disease progression. However, tracking these changes often involves repeated... Read more

Point of Care

view channel
Image: Jessica Ramella-Roman, professor of biomedical engineering at Florida International University, holding the PPRIM (Portable Preterm Imaging) device designed to detect early signs of preterm labor risk. (Photo courtesy of Florida International University)

Handheld Imaging Device May Help Identify Preterm Birth Risk Earlier

Preterm birth, defined as delivery before 37 weeks of pregnancy, can lead to serious neonatal complications, including neurological, developmental, and respiratory problems. However, identifying pregnancies... Read more

Business

view channel
Image: Stryker has acquired ZuriMED, adding the FiberLocker System, a rotator cuff augmentation technology designed to strengthen repairs, to its Sports Medicine portfolio. (Photo courtesy of ZuriMED)

Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings

Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.